Bioabsorbable Drug-Eluting Stents May Solve Lingering Thrombosis Problem
This article was originally published in The Gray Sheet
Executive Summary
Late thrombosis caused by drug-eluting stents could be eliminated with the development of new bioabsorbable stents, Ron Waksman, MD, suggested March 29 at the CRT conference in Washington, D.C
You may also be interested in...
First Bioabsorbable Drug-Eluting Stent Implanted In Guidant Trial
"It melts in your artery, not in your hand" might be an appropriate tag line for a next-generation stent product from Guidant that just entered clinical trials
First Bioabsorbable Drug-Eluting Stent Implanted In Guidant Trial
"It melts in your artery, not in your hand" might be an appropriate tag line for a next-generation stent product from Guidant that just entered clinical trials
Rithron XR Approval Is Part Of Larger U.S. Vascular Intervention Strategy
FDA approval of Biotronik's Rithron XR coronary stent marks a first step in the firm's long-term strategy to enter the U.S. vascular intervention market